AI assistant
NYRADA INC. — Major Shareholding Notification 2021
Mar 24, 2021
65469_rns_2021-03-24_9980c4ce-2cb6-4c09-af01-3f06488ed4ae.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
==> picture [596 x 114] intentionally omitted <==
25 March 2021
Sydney, Australia
Notice of Change of Interests of Substantial Securityholder
Sydney, 25 March 2021: Nyrada Inc (ASX: NYR), advises, further to the Deed Poll dated 6 January 2020 issued by the Company in favour of ASX Limited in respect of the Initial Public Offering of its Chess Depositary Interests (“CDIs”), a Change of Interests of a Substantial Holder in relation to Nyrada. Details of the change in CDIs (“Relevant Interests”) are as follows:
Name of Substantial Holder of Relevant Interests: Eleanore Goodridge Date of change in the interests of the Substantial Holder : 24 March 2021
Previous and present voting power of Substantial Holder (through CHESS Depository Nominees Pty Ltd):
| Nominees Pty Ltd): | Nominees Pty Ltd): | ||
|---|---|---|---|
| Previous notice | Present notice | ||
| Number of CDIs | Voting power | Number of CDIs | Voting Power |
| 7,024,832 | 6.42% | 5,974,832 | 5.39% |
Present Relevant Interests:
| Present Relevant Interests: | |||
|---|---|---|---|
| Holder of Relevant Interest |
Registered Holdings of CDIs |
Relevant Interest Number of CDIs |
Voting Power |
| Eleanore Goodridge | Goodridge Nominees Pty Ltd atf The Goodridge Family A/C |
4,762,416 (1) | 4.30% |
| Eleanore Goodridge | Goodridge Foundation Pty Ltd atf The Goodridge Foundation |
1,212,416 (1) | 1.09% |
(1) includes 1,212,416 CDIs in each holding escrowed for 24 months from IPO
-ENDS-
Nyrada Inc. Level 4, 828 Pacific Highway GORDON, NSW 2072
Nyrada Inc. ARBN 625 401 818
==> picture [596 x 114] intentionally omitted <==
About Nyrada Inc
Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.
www.nyrada.com
Authorised by John Moore, Non-Executive Chairman
Investor & Corporate Enquiries:
Investor & Corporate Enquiries: Company Secretary: Laura Vize David Franks Investor Relations Manager T: 02 8072 1400 T: 0417 026 056 E: [email protected] E: [email protected]
Media Enquiries:
Catherine Strong Citadel-MAGNUS T: 02 8234 0111 E: [email protected]
Nyrada Inc. Level 4, 828 Pacific Highway GORDON, NSW 2072
Nyrada Inc. ARBN 625 401 818